Medistim — Earnings Release 2025

May 9, 2025

First quarter 2025 financial results and status for Medistim ASA

First quarter 2025 financial results and status for Medistim ASA

An exceptionally strong quarter for sales revenues, 20.1 % above the previous record, ending at MNOK 181.5. This is growth of 35.7 % compared to first quarter last year (MNOK 133.8).

Currency neutral sales of own products were up 29.9 % for the quarter.

Strong growth in all geographies with AMERICAS up 28.4 %, EMEA up 18.2 % and APAC up 62.6 %, currency neutral.

Third-party distributor sales in Scandinavia increased 41.2 % for the quarter.

Operating profit (EBIT) grew by 84.5 % and ended at MNOK 59.2 giving a 32.6 % EBIT margin (MNOK 32.1, 24.0 % margin)

Recurring sales remained high, but strong capital sales reduce recurring sales in percent to 68 % (75 %) compared to same quarter last year.

Medistim strengthened its commercial operation by appointing a Chief Commercial Officer and a new VP Sales for AMERICAS.

Solid cash position at quarter end with MNOK 183.4 and no interest-bearing liabilities.

The General Meeting decided a dividend of NOK 6.00 per share (NOK 4.5), total MNOK 109.6 (MNOK 82.4).